Rosiglitazone Improves Glucose Metabolism in Obese Adolescents With Impaired Glucose Tolerance: A Pilot Study

被引:10
作者
Cali, Anna M. G. [1 ,2 ]
Pierpont, Bridget M. [1 ]
Taksali, Sara E. [1 ]
Allen, Karin [3 ]
Shaw, Melissa M. [1 ]
Savoye, Mary [3 ]
Caprio, Sonia [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA
[2] Univ Cambridge, Dept Clin Biochem, Cambridge, England
[3] Yale Univ, Sch Med, YCCI, New Haven, CT USA
基金
美国国家卫生研究院;
关键词
PREVENTS;
D O I
10.1038/oby.2010.109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Impaired glucose tolerance (IGT) is a prediabetic state fueling the rising prevalence of type 2 diabetes mellitus (T2DM) in adolescents with marked obesity. Given the importance of insulin resistance, the poor beta-cell compensation and the altered fat partitioning as underlying defects associated with this condition, it is crucial to determine the extent to which these underlying abnormalities can be reversed in obese adolescents. We tested, in a pilot study, whether rosiglitazone (ROSI) restores normal glucose tolerance (NGT) in obese adolescents with IGT by improving insulin sensitivity and beta-cell function. In a small randomized, double-blind, placebo (PLA)-controlled study, lasting 4 months, 21 obese adolescents with IGT received either ROSI (8 mg daily) (n = 12, 5M/7F, BMI z-score 2.44 +/- 0.11) or PLA (n = 9, 4M/5F, BMI z-score 2.41 +/- 0.09). Before and after treatment, all subjects underwent oral glucose tolerance test (OGTT), hyperinsulinemic-euglycemic clamp, magnetic resonance imaging, and H-1 NMR assessment. After ROSI treatment, 58% of the subjects converted to NGT compared to 44% in the PLA group (P = 0.528). Restoration of NGT was associated with a significant increase in insulin sensitivity (P < 0.04) and a doubling in the disposition index (DI) (P < 0.04), whereas in the PLA group, these changes were not significant. The short-term use of ROSI appears to be safe in obese adolescents with IGT. ROSI restores NGT by increasing peripheral insulin sensitivity and beta-cell function, two principal pathophysiological abnormalities of IGT.
引用
收藏
页码:94 / 99
页数:6
相关论文
共 19 条
[1]  
Amer Diabet Assoc, 2012, DIABETES CARE, V35, pS64, DOI [10.2337/dc19-S002, 10.2337/dc12-S064, 10.2337/dc23-S002, 10.2337/dc09-S062, 10.2337/dc18-S002]
[2]   Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance [J].
Burgert, Tania S. ;
Duran, Elvira J. ;
Goldberg-Gell, Rachel ;
Dziura, James ;
Yeckel, Catherine W. ;
Katz, Stuart ;
Tamborlane, William V. ;
Caprio, Sonia .
PEDIATRIC DIABETES, 2008, 9 (06) :567-576
[3]   Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents [J].
Cali, Anna M. G. ;
Bonadonna, Riccardo C. ;
Trombetta, Maddalena ;
Weiss, Ram ;
Caprio, Sonia .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (05) :1767-1773
[4]   Introduction of fast MR imaging in the assessment of hepatic steatosis [J].
Fishbein, MH ;
Gardner, KG ;
Potter, CJ ;
Schmalbrock, P ;
Smith, MA .
MAGNETIC RESONANCE IMAGING, 1997, 15 (03) :287-293
[5]   Thiazolidinediones improve β-cell function in type 2 diabetic patients [J].
Gastaldelli, Amalia ;
Ferrannini, Ele ;
Miyazaki, Yoshinori ;
Matsuda, Masafumi ;
Mari, Andrea ;
DeFronzo, Ralph A. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 292 (03) :E871-E883
[6]   Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].
Gerstein, H. C. ;
Yusuf, S. ;
Holman, R. R. ;
Bosch, J. ;
Anand, S. ;
Avezum, A. ;
Budaj, A. ;
Chiasson, J. ;
Conget, I. ;
Dagenais, G. ;
Davis, M. ;
Diaz, R. ;
Dinccag, N. ;
Enjalbert, M. ;
Escalante, A. ;
Fodor, G. ;
Hanefeld, M. ;
Hedner, T. ;
Jolly, K. ;
Keltai, M. ;
Laakso, M. ;
Lanas, F. ;
Lonn, E. ;
McQueen, M. ;
Mohan, V. ;
Phillips, A. ;
Piegas, L. ;
Pirags, V. ;
Probstfield, J. ;
Shaw, J. ;
Schmid, I. ;
Teo, K. ;
Zimmet, P. ;
Zinman, B. ;
Gerstein, H. C. ;
Yusuf, S. ;
Bosch, J. ;
Pogue, J. ;
Sheridan, P. ;
Dinccag, N. ;
Hanefeld, M. ;
Hoogwerf, B. ;
Laakso, M. ;
Mohan, V. ;
Shaw, J. ;
Zinman, B. ;
Holman, R. R. ;
Diaz, R. ;
Ahuad Guerrero, R. ;
Albisu, J. .
LANCET, 2006, 368 (9541) :1096-1105
[7]   Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice:: Possible protection of β cells from oxidative stress [J].
Ishida, H ;
Takizawa, M ;
Ozawa, S ;
Nakamichi, Y ;
Yamaguchi, S ;
Katsuta, H ;
Tanaka, T ;
Maruyama, M ;
Katahira, H ;
Yoshimoto, K ;
Itagaki, E ;
Nagamatsu, S .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (04) :488-494
[8]   Rosiglitazone prevents the impairment of human islet function induced by fatty acids:: evidence for a role of PPARγ2 in the modulation of insulin secretion [J].
Lupi, R ;
Del Guerra, S ;
Marselli, L ;
Bugliani, M ;
Boggi, U ;
Mosca, F ;
Marchetti, P ;
Del Prato, S .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 286 (04) :E560-E567
[9]   Insulin sensitivity indices obtained from oral glucose tolerance testing - Comparison with the euglycemic insulin clamp [J].
Matsuda, M ;
DeFronzo, RA .
DIABETES CARE, 1999, 22 (09) :1462-1470
[10]  
Miyazaki Y, 2001, DIABETOLOGIA, V44, pA37